NY Times DealBook – A Case for Rejecting Pfizer’s Bid for AstraZeneca
Published on May 8, 2014
Is the role of leading large pharmaceutical companies to discover life-saving drugs or to make money for shareholders through financial engineering? Pfizer claims “both,” I don’t believe pharmaceutical companies can create long-term shareholder value by focusing solely on chasing lower tax venues and cutting research and development spending. Read more in my New York Times Dealbook article.